Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Merck's LAG-3 combo fails colorectal cancer phase 3 study
The fixed-dose combination failed to improve overall survival, extending the wait for a checkpoint inhibitor that moves the needle in the indication.
Nick Paul Taylor
Sep 25, 2024 8:35am
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
Sep 20, 2024 7:07am
Atea's COVID antiviral fails to halt hospitalizations in phase 3
Sep 13, 2024 10:10am
Neurocrine's bid to save schizophrenia prospect fails
Sep 13, 2024 7:30am
Sanofi's $80M bet on Fulcrum dystrophy drug ends in phase 3 fail
Sep 12, 2024 9:30am
GSK surrenders HSV vaccine hopes after phase 2 fail
Sep 11, 2024 4:21am